A study on clinical characteristics of gestational diabetes mellitus associated with intrauterine fetal death

Monteiro, Geraldine; Nk, Subbalakshmi; Pai, Sheila R

doi:10.7439/ijbr.v5i1.390

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient who had IUFD during the study was compliant and blood glucose were under control, the patient had additional risk factor of gestational hypertension with blood pressure in the range of 140-150 /90-100 mm hg, the cause of IUD could not be related to glibenclamide and could be related to high recording of BP which is similar to study conducted by Subbalakshmi et al where they found that intrauterine fetal death could be associated with raised blood pressure in mothers with gestational diabetes mellitus. 15 In our study, 03 (03%) patients delivered a neonate weighing less than 2.5kg and 01 (01%) delivered a neonate weighing more than 4 kg. In glibenclamide group 02 (04%) patients delivered a neonate weighing less than 2.5 kg and 01 (02%) patient delivered a neonate weighing more than 4 kg.…”

Section: Discussionmentioning

confidence: 57%

A comparative study of using glibenclamide versus insulin in the treatment of gestational diabetes mellitus and its outcome

Rao

Datta

Prajwal

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Gestational diabetes mellitus(GDM) is defined as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy. This study aims at determining the efficacy of the glibenclamide versus insulin in achieving the adequate glycemic control and to analyze the maternal and fetal outcomes and to determine the failure rate of glibenclamide, patient compliance and overall cost of the treatmentMethods: This study was carried out for a period of 22 months at Command Hospital Air Force, Bangalore in Dept. of OBG. Women with GDM whose glycemic control was not achieved with medical nutrition therapy with fasting blood sugar (FBS) values >105mg/dl and 2hour post prandial blood sugar (PP) value >140mg/dl were selected and randomized for treatment either glibenclamide or insulin (50 in each group).Results: The age of the patients in this study ranged from 23 to 33 years. The mean age in glibenclamide group was 27.32 (SD ± 2.84) where as in insulin group was 26.30 (SD ± 3.01). The mean plasma glucose level achieved with glibenclamide was fasting -87.62 mg/dl, post prandial -116.44 mg/dl, before lunch - 95.62mg/dl, after lunch -115.80 mg/dl, before dinner-91.96 mg/dl, after dinner - 116.64 mg/dl, 3AM - 84.42 mg/dl and next day fasting - 86.30mg/dl in comparison with insulin where fasting- 85.54 mg/dl , post prandial -114.14 mg/dl, before lunch - 87.08, after lunch -112.82 mg/dl, before dinner-86.76 mg/dl and after dinner - 114.18 mg/dl, 3AM - 81.16 mg/dl and next day fasting was 86.72mg/dl which is statistically significant. The incidence of maternal and neonatal morbidities was comparable in both the group. 4 % percent of patient treated with glibenclamide had treatment failure. The cost of the treatment and compliance was better with glibenclamide.Conclusions: It has been concluded that glibenclamide is effective as insulin in achieving adequate glycemic control with no significant maternal and fetal morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 57%